SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Eisenstat David D.)
 

Sökning: WFRF:(Eisenstat David D.) > (2015) > Molecular subgroups...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006335naa a2201129 4500
001oai:DiVA.org:uu-255273
003SwePub
008150615s2015 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2552732 URI
024a https://doi.org/10.1016/S1470-2045(15)70114-22 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Torchia, Jonathon4 aut
2451 0a Molecular subgroups of atypical teratoid rhabdoid tumours in children :b an integrated genomic and clinicopathological analysis
264 1c 2015
338 a print2 rdacarrier
520 a Background Rhabdoid brain tumours, also called atypical teratoid rhabdoid tumours, are lethal childhood cancers with characteristic genetic alterations of SMARCB1/hSNF5. Lack of biological understanding of the substantial clinical heterogeneity of these tumours restricts therapeutic advances. We integrated genomic and clinicopathological analyses of a cohort of patients with atypical teratoid rhabdoid tumours to find out the molecular basis for clinical heterogeneity in these tumours. Methods We obtained 259 rhabdoid tumours from 37 international institutions and assessed transcriptional profiles in 43 primary tumours and copy number profiles in 38 primary tumours to discover molecular subgroups of atypical teratoid rhabdoid tumours. We used gene and pathway enrichment analyses to discover group-specific molecular markers and did immunohistochemical analyses on 125 primary tumours to evaluate clinicopathological significance of molecular subgroup and ASCL1-NOTCH signalling. Findings Transcriptional analyses identified two atypical teratoid rhabdoid tumour subgroups with differential enrichment of genetic pathways, and distinct clinicopathological and survival features. Expression of ASCL1, a regulator of NOTCH signalling, correlated with supratentorial location (p=0.004) and superior 5-year overall survival (35%, 95% CI 13-57, and 20%, 6-34, for ASCL1-positive and ASCL1-negative tumours, respectively; p=0.033) in 70 patients who received multimodal treatment. ASCL1 expression also correlated with superior 5-year overall survival (34%, 7-61, and 9%, 0-21, for ASCL1-positive and ASCL1-negative tumours, respectively; p=0.001) in 39 patients who received only chemotherapy without radiation. Cox hazard ratios for overall survival in patients with differential ASCL1 enrichment treated with chemotherapy with or without radiation were 2.02 (95% CI 1.04-3.85; p=0.038) and 3.98 (1.71-9.26; p=0.001). Integrated analyses of molecular subgroupings with clinical prognostic factors showed three distinct clinical risk groups of tumours with different therapeutic outcomes. Interpretation An integration of clinical risk factors and tumour molecular groups can be used to identify patients who are likely to have improved long-term radiation-free survival and might help therapeutic stratification of patients with atypical teratoid rhabdoid tumours.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700a Picard, Daniel4 aut
700a Lafay-Cousin, Lucie4 aut
700a Hawkins, Cynthia E.4 aut
700a Kim, Seung-Ki4 aut
700a Letourneau, Louis4 aut
700a Ra, Young-Shin4 aut
700a Ho, King Ching4 aut
700a Chan, Tiffany Sin Yu4 aut
700a Sin-Chan, Patrick4 aut
700a Dunham, Christopher P.4 aut
700a Yip, Stephen4 aut
700a Ng, Ho-Keung4 aut
700a Lu, Jian-Qiang4 aut
700a Albrecht, Steffen4 aut
700a Pimentel, Jose4 aut
700a Chan, Jennifer A.4 aut
700a Somers, Gino R.4 aut
700a Zielenska, Maria4 aut
700a Faria, Claudia C.4 aut
700a Roque, Lucia4 aut
700a Baskin, Berivanu Uppsala universitet,Medicinsk genetik och genomik4 aut0 (Swepub:uu)berba972
700a Birks, Diane4 aut
700a Foreman, Nick4 aut
700a Strother, Douglas4 aut
700a Klekner, Almos4 aut
700a Garami, Miklos4 aut
700a Hauser, Peter4 aut
700a Hortobagyi, Tibor4 aut
700a Bognar, Laszlo4 aut
700a Wilson, Beverly4 aut
700a Hukin, Juliette4 aut
700a Carret, Anne-Sophie4 aut
700a Van Meter, Timothy E.4 aut
700a Nakamura, Hideo4 aut
700a Toledano, Helen4 aut
700a Fried, Iris4 aut
700a Fults, Daniel4 aut
700a Wataya, Takafumi4 aut
700a Fryer, Chris4 aut
700a Eisenstat, David D.4 aut
700a Scheineman, Katrin4 aut
700a Johnston, Donna4 aut
700a Michaud, Jean4 aut
700a Zelcer, Shayna4 aut
700a Hammond, Robert4 aut
700a Ramsay, David A.4 aut
700a Fleming, Adam J.4 aut
700a Lulla, Rishi R.4 aut
700a Fangusaro, Jason R.4 aut
700a Sirachainan, Nongnuch4 aut
700a Larbcharoensub, Noppadol4 aut
700a Hongeng, Suradej4 aut
700a Barakzai, Muhammad Abrar4 aut
700a Montpetit, Alexandre4 aut
700a Stephens, Derek4 aut
700a Grundy, Richard G.4 aut
700a Schueller, Ulrich4 aut
700a Nicolaides, Theodore4 aut
700a Tihan, Tarik4 aut
700a Phillips, Joanna4 aut
700a Taylor, Michael D.4 aut
700a Rutka, James T.4 aut
700a Dirks, Peter4 aut
700a Bader, Gary D.4 aut
700a Warmuth-Metz, Monika4 aut
700a Rutkowski, Stefan4 aut
700a Pietsch, Torsten4 aut
700a Judkins, Alexander R.4 aut
700a Jabado, Nada4 aut
700a Bouffet, Eric4 aut
700a Huang, Annie4 aut
710a Uppsala universitetb Medicinsk genetik och genomik4 org
773t The Lancet Oncologyg 16:5, s. 569-582q 16:5<569-582x 1470-2045x 1474-5488
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-255273
8564 8u https://doi.org/10.1016/S1470-2045(15)70114-2

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy